BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Golledge J, Thanigaimani S. Role of Sclerostin in Cardiovascular Disease. Arterioscler Thromb Vasc Biol 2022;42:e187-202. [PMID: 35546488 DOI: 10.1161/ATVBAHA.122.317635] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Williams MJ, White SC, Joseph Z, Hruska KA. Updates in the chronic kidney disease-mineral bone disorder show the role of osteocytic proteins, a potential mechanism of the bone—Vascular paradox, a therapeutic target, and a biomarker. Front Physiol 2023;14. [DOI: 10.3389/fphys.2023.1120308] [Reference Citation Analysis]
2 Garcia-de Los Ríos C, Medina-Casado M, Díaz-Chamorro A, Sierras-Jiménez M, Lardelli-Claret P, Cáliz-Cáliz R, Sabio JM. Sclerostin as a biomarker of cardiovascular risk in women with systemic lupus erythematosus. Sci Rep 2022;12:21621. [PMID: 36517533 DOI: 10.1038/s41598-022-25651-y] [Reference Citation Analysis]
3 Sanabria-de la Torre R, González-Salvatierra S, García-Fontana C, Andújar-Vera F, García-Fontana B, Muñoz-Torres M, Riquelme-Gallego B. Exploring the Role of Sclerostin as a Biomarker of Cardiovascular Disease and Mortality: A Scoping Review. Int J Environ Res Public Health 2022;19. [PMID: 36498053 DOI: 10.3390/ijerph192315981] [Reference Citation Analysis]
4 Lim SY. Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk. Womens Health (Lond Engl) 2022;18:174550572211255. [DOI: 10.1177/17455057221125577] [Reference Citation Analysis]